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Original Article

Undetectable Mannose Binding Lectin and
Corticosteroids Increase Serious Infection Risk in
Rheumatoid Arthritis
Graeme J. Carroll, MDa,b,c,d, Krista Makin, MBBSc, Maxine Garnsey, MBBSe, Max Bulsara, PhDa,
Bronwyn V. Carroll, MBBSc, Shona M. Curtin, MBBSe, Erin M. Allan, BEngd, Andrew McLean-Tooke, MDf,
Christine Bundell, PhDf, Monica L. Kemp, MScf, Pooja Deshpande, MScg, Dana Ihdayhid, MBBSc, Sophie Coleman, PhDd,
Tracie Easter, MScf, James Triplett, MMedh, Timothy Disteldorf, MBBSg, C. Helen Marsden, MScb,c, and
Michaela Lucas, MDe,f,i,j Fremantle, Perth, and Mt Lawley, Western Australia, Australia

What is already known about this topic? Serious infections (SIs) are the leading cause of death in rheumatoid arthritis.
Several clinical factors and most importantly prolonged corticosteroid use confer risk for SIs. So far, no serological predictor for SIs has been identiﬁed.
What does this article add to our knowledge? Mannose binding lectin (MBL) deﬁciency has been found to confer
increased risk for SIs, comparable to the use of maintenance prednisolone.
How does this study impact current management guidelines? Knowledge of MBL status will emphasize SI risk and
inform treatment decision making in rheumatoid arthritis. These ﬁndings are likely to inform clinical practice.
BACKGROUND: Infection is the leading cause of death in
rheumatoid arthritis (RA). Corticosteroid (CS) use is a known
and important risk factor for serious infections (SIs). Mannose
binding lectin (MBL) is a genetically determined component of
the innate immune system implicated in neonatal infections.
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OBJECTIVE: Our aim was to determine whether MBL
deﬁciency is a risk factor for SIs in RA and to compare it with CS
use and also synthetic and biologic disease-modifying antirheumatic drug (DMARD) therapy.
METHODS: Data on 228 patients with RA were collected for up
to 7 years (median [ 5.9 years). Serum MBL concentrations
were determined in all patients receiving synthetic (n [ 96) or
biologic (n [ 132) DMARD therapy.
RESULTS: High rates of SIs were observed in RA irrespective of
treatment (17%). Similar rates of SIs were observed in synthetic
and biologic DMARD users. The rates of single and multiple SIs
were similar, irrespective of the use of a biologic agent.
Undetectable MBL (<56 ng/mL) concentrations and
maintenance prednisolone at 10 mg per day or higher were
associated with an increased risk for an SI, with incident risk
ratio of 4.67 (P [ .001) and 4.70 (P < .001), respectively.
CONCLUSIONS: Undetectable MBL and prednisolone confer a
high risk for an SI. The use of biologic DMARDs did not confer
substantial SI risk in this observational study. MBL deﬁciency is
hitherto an unrecognized risk factor for an SI in RA. Ó 2017
The Authors. Published by Elsevier Inc. on behalf of the
American Academy of Allergy, Asthma & Immunology. This is
an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/). (J Allergy Clin
Immunol Pract 2017;5:1609-16)
Key words: Rheumatoid arthritis; Serious infection; Mannose
binding lectin; Immune system; Risk factor

Serious infections (SIs) are still the leading global cause of
death in patients with rheumatoid arthritis (RA). Known risk
factors for SIs in RA include increasing age, use of corticosteroids
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Abbreviations used
bDMARD- Biologic disease-modifying antirheumatic drug
COPD- Chronic obstructive pulmonary disease
CS- Corticosteroids
DMARD- Disease-modifying antirheumatic drug
ICC- Intraclass coefﬁcient
IRR- Incident risk ratio
MBL- Mannose binding lectin
OR- Odds ratio
PY- Patient year
RA- Rheumatoid arthritis
sDMARD- Synthetic disease-modifying antirheumatic drug
SI- Serious infection
SNP- Single nucleotide polymorphism

(CS), and neutropenia, particularly in Felty’s syndrome.1,2 The
inability to predict which patients will develop an SI represents
an important unmet clinical need.
Mannose binding lectin (MBL) is a serum protein produced
in the liver, which acts as a pattern recognition receptor.3,4 MBL
recognizes carbohydrate moieties on the surface of diverse
microbes, including bacteria, viruses, fungi, and parasites. MBL
binding results in the killing of microorganisms by the activation
of the complement system with subsequent complementmediated microbial lysis and phagocytosis of the microbe due
to the opsonizing effect of C3b production.5 The MBL glycoprotein in human serum is the product of the polymorphic
MBL2 gene located on chromosome 10. Approximately 5% to
9% of the Caucasian population have very low concentrations of
MBL (<56 ng/mL).6 MBL deﬁciency has been associated with
an increased susceptibility to infection in neonates, in young
children with recurrent serious infections, and in adults with
iatrogenic neutropenia.7-9
To evaluate risk factors for SIs in RA, an audit of an RA
cohort was undertaken over a period of 7 years. In addition to
established clinical and known laboratory parameters likely to
increase risk, we also evaluated the potential for MBL serum
concentration to confer the risk for an SI.

METHODS
The study was designed as an observational data audit. The
project was evaluated by Fremantle Hospital and Sir Charles
Gairdner Hospital Ethics and Human Rights Committees and given
ethical approval (FH HREC 12/10 and SCGH HREC 2013-091).
A waiver of consent was granted. No identifying details have been
included in the article.
Participants were patients with RA of at least 6 months’ duration
who met the 1987 American College of Rheumatology diagnostic
criteria10 and who presented to private, public, or rural rheumatology clinics after January 1, 2007. Data were collected up to
the April 30, 2014 (Table I). Data collection began when the
patients either commenced a disease-modifying antirheumatic drug
(DMARD) other than hydroxychloroquine or prednisolone, such as
azathioprine, cyclosporine, leﬂunomide, methotrexate, or sulfasalazine, or when they commenced a biologic agent. Prednisolone is
commonly used in Australia and is available in the form of 1 mg, 5
mg, and 25 mg. Its potency is similar to that of prednisone (1:1).11
Patients who changed category, for example, a synthetic to biologic
agent, were analyzed thereafter as biologic recipients. When participants switched to another biologic, they continued to be studied,
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and for the purpose of further analyses such as those shown in
Table II, the biologic used for the longest period of time was
assigned to those participants.
Biologic DMARDs (bDMARDs) include adalimumab, etanercept,
inﬂiximab, abatacept, rituximab, and tocilizumab. The internationally
accepted deﬁnition for an SI was used, that is, infections that required
hospital admission or treatment with intravenous antibiotics, with or
without hospital admission.12
From January 1, 2007, to April 30, 2014, details concerning SIs
were obtained by questioning at the time of the clinical review.
Accordingly, every 3 to 6 months for the duration of the study, SIs
were solicited by the attending physician. In May-June 2014, we
conducted a retrospective audit of hospital admission records for all
participants. A state-wide government health database was interrogated by 2 members of the investigative team. When an SI was
conﬁrmed, its nature and the outcome of treatment was recorded.
In the month before commencement of synthetic or biologic
DMARD therapy, the following investigations were performed:
hepatitis B and C serology, QuantiFERON Gold testing for latent
tuberculosis, serum MBL, serum immunoglobulins, and total
neutrophil and lymphocyte counts. All participants had an MBL
assay for the ﬁrst time in conjunction with the other preliminary
presynthetic DMARD or prebiologic tests as cited above. The
choice of treatment was not inﬂuenced by the serum MBL
concentration.

Measurement of serum MBL
The MBL Oligomer ELISA kit (Bioporto, Hellerup, Denmark)
was used to determine the concentration of oligomerized MBL in
human serum as per the manufacturer’s instructions. In brief,
microwells coated with a monoclonal antibody against the MBL
carbohydrate-binding domain were incubated with diluted patient
serum. Bound MBL was detected with a biotinylated MBL antibody
and subsequent development using a horseradish peroxidase conjugated streptavidin tetramethylbenzidine substrate. In this assay, the
intensity of the resulting colored product is directly proportional to
the concentration of MBL in the serum. It should be noted that the
assay determines MBL concentrations and does not assess MBL
function. The lower limit of detection for this assay was 56 ng/mL.13
The threshold of 56 ng/mL is based on a historical and current
cutoff reported by the Western Australian Pathology Laboratory.
When the assay was ﬁrst introduced, the lower limit of detection in
our laboratory was determined to be <56 ng/mL, based on the
standards included in the measurements. As some of the samples
used in this study were measured at this initial time, we maintained
this threshold for all samples. We acknowledge that the assay can
measure lower values, and the currently most used cutoff in the
literature is 50 ng/mL.
The reference intervals for MBL concentrations are based on
published data from comparable populations.14,15

Statistical analysis
Descriptive statistics are presented as means and standard
deviations for continuous variables and as percentages for categorical
variables. Statistical analysis was carried out using simple parametric
tests as well as negative binomial regression models (to investigate
factors related to the incidence of SIs) and logistic regression models
(to investigate factors related to multiple SIs). Rate ratios and
95% conﬁdence intervals are reported. All the statistical analyses
were carried out using Stata v13.7.16
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TABLE I. Participant characteristics
Caucasian 99.6%

Male (n ¼ 74)
Female (n ¼ 154)
Male MBL level
Female MBL level
Median age
Rural
Urban
Median disease duration at baseline (y)
Median number of DMARDs
Corticosteroid at baseline
Rheumatoid factor positive
CCP† antibody positive
Neutropenia (2.0  109/L)
Diabetes type 1 or 2
Smokers (past and present)
COPD
Interstitial lung disease

Synthetic DMARD (n [ 96)

42 (44%)
54 (56%)
<56
56-399
5
4
<56
56-399
11
6
68 (range 24-90)
13 (14%)
83 (86%)
10 (range 0.5-52)
1 (range 0-5)
9 (9%)
49 (67%* of 73 samples)
17 (41%* of 41 samples)
3 (3%)
10 (13%)
34 (49%)
9 (10%)
5 (6%)

399-1299
33
399-1299
37

Biologic DMARD (n [ 132)

32 (25%)
100 (76%)
<56
56-399
4
5
<56
56-399
13
19
64 (range 21-93)
28 (21%)
104 (79%)
11 (range 1-46)
2 (range 0-8)
23 (17%)
77 (74%* of 104 samples)
28 (67%* of 42 samples)
4 (3%)
7 (7%)
35 (31%)
11 (8%)
9 (7%)

P value

.002
399-1299
23
399-1299
68
.031
.136

.004
.317

.084
.019
.638
.709

CCP, Cyclic citrullinated peptides; COPD, chronic obstructive pulmonary disease; DMARD, disease-modifying antirheumatic drug; MBL, mannose binding lectin.
*Indicates the number positive as a percent of the number of available samples. Some participants did not have rheumatoid factor or CCP sera available for assays.
†CCP are frequently used to detect autoantibodies in patient serum or plasma (then referred to as anticitrullinated peptide antibodies).10

RESULTS
In total, 228 participants who satisﬁed the 1987 American
College of Rheumatology criteria for the diagnosis of RA were
audited, the demographic data for whom are shown in Table I.
Ninety-six participants (42 males and 54 females), median age 68
years, received synthetic DMARDs (sDMARDs) alone; and 132
participants (32 males and 100 females), median age 64 years,
received bDMARDs with or without sDMARDs. Of the cohort,
18% lived in rural areas of Western Australia, and 82% lived in
urban areas. Socioeconomic, education, employment status, income, or area-based measures of disadvantage were not collected.
Seven participants, 4 of whom did not develop SIs,
had neutropenia (1.5 to 2.0 neutrophils/nL; normal 2.0 to
7.5  109/L) in the full blood count performed closest to the
time of the MBL measurement. None had Felty’s syndrome.
Two had hypogammaglobulinemia with IgG concentrations
of 5.9 and 5.5 g/L (normal 6.10 to 13.00 g/L) and IgM concentrations of 0.3 and 0.9 g/L (normal 0.83 to 3.32 g/L),
respectively. Twenty-two participants died (9.6%) and 18
participants were lost to follow-up (7.9%).
The mean duration of observation was 5.92 years (SD ¼ 1.63,
n ¼ 228). The 132 participants in the bDMARD group received
the bDMARD, either alone (n ¼ 42) or in combination with
one or more sDMARDs (n ¼ 90). The types of DMARDs and
the relative proportion of each are shown in Table II. Single SIs
were observed in 48 (21%) participants (18/96 in the sDMARD
group and 30/132 in the bDMARD group). Multiple SIs (2 or
more, median ¼ 2, range 2-14) were observed in 30 (13%)
participants (11/96 and 19/132, respectively).
Thus, patients receiving bDMARDs, compared with
sDMARDs, had a similar incidence of SIs (incident risk ratio
[IRR] ¼ 0.90; 95% CI 0.64-1.27), after controlling for age and
gender.

In 18 study participants, the MBL was measured at more than
1 time point. These patients were identiﬁed retrospectively to
have had repeat testing in the same laboratory; hence they were
not selected based on clinical characteristics. We did not deliberately choose to repeat the assay in any participants in the study
and in particular not in those who were found to have SIs.
The repetition was inadvertent and coincidental. The intraclass
coefﬁcient (ICC) was calculated to assess the reliability of the
MBL assay. The ICC value using a 2-way random effect model
was found to be 0.93, 95% CI 0.67 to 0.98, indicating a high
degree of measurement reliability.
Additionally, we audited data in our laboratory to assess the
changes in MBL measurements in an individual over time.
Over the past 10 years, 5761 MBL measurements were performed in our routine diagnostic laboratory. In 331 subjects, at
least 1 repeat measurement of the MBL concentration was
performed. A strong correlation between repeated measures was
observed over time. Spearman’s rank-order correlation
coefﬁcient ¼ 0.9258 (CI 0.9081-0.9402; P < .0001). In those
with more than 1 repeat testing, the correlation between the
ﬁrst 5 tests ranged from 0.860 to 0.968 (P < .01). The range of
time between measurements was 0 to 9.1 years. The greatest
ﬂuctuation in concentration was detected in those with higher
concentrations of serum MBL (Figure 1). The least ﬂuctuation
was observed in persons with low concentrations, which
strengthens our conﬁdence in the reliability of single measurements that yield low concentrations compatible with
genetic MBL deﬁciency.
Furthermore, whether testing for genetic variation within the
MBL gene in conjunction with serum MBL concentrations
provides additional information remains unclear. There are
5 known single nucleotide polymorphisms (SNPs) that affect the
level of serum MBL concentrations. Codon 52 (minor allele D),
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TABLE II. Types of serious infections according to treatment and MBL concentration (undetectable or detectable)
Synthetic DMARD
No. (n [ 63)

Type of Infection

Respiratory
Urological
Gastrointestinal
Skin
Septicemia
Joint, bone, and muscle combined
Septic arthritis
Other
Biologic agent

Etanercept
Adalimumab
Rituximab
Abatacept
Tocilizumab
Inﬂiximab
Total

33
6
4
7
6
4
2
1

No.(percentage of total)

91
28
5
4
3
1
132

Biologic DMARD

No. (%) with MBL <56

19
3
0
0
1
3
1
0

No. (n [ 92)

(58)
(50)
(0)
(0)
(17)
(75)
(50)
(0)

23
13
7
21
8
11
6
3

Female/Male

% Female

Rural/Urban

Percentage
of Rural

65/26
25/3
4/1
3/1
3/0
1/0
100/32

71
89
80
75
100
100
76

18/73
8/20
0/5
2/2
0/3
0/1
28/104

20
29
0
50
0
0
21

(69%)
(21%)
(4%)
(3%)
(2%)
(1%)
(100%)

No. (%) with MBL <56

Age (y)
Median (range)

65
73
64
61
75

(26-95)
(43-94)
(49-83)
(35-65)
(54-78)
79
65 (27-95)

7
1
3
4
1
8
5
0

(30)
(8)
(43)
(19)
(13)
(73)
(83)
(0)

DAS28
Median (range)

2.64
3.68
4.4
3.32

(0.14-7.22)
(1.02-4.93)
(1.84-5.88)
(1.25-4.5)
NA
NA
2.85 (0.14-7.22)

P value

.045
.426
.216
.545
1.0
1.0

% RF positive/%
CCP positive

74/70 (30*)
61/40 (5*)
75/67 (3*)
67/50 (2*)
100/100 (2*)
100/NA
74/67 (42*)

The biologic DMARD used for the longest period of time for any given patient was recorded in those patients who changed agents. Biologic DMARDs were not used in
combination.
CCP, Cyclic citrullinated peptides; DMARD, disease-modifying antirheumatic drug; MBL, mannose binding lectin; NA, not available due to small numbers or no testing;
RF, rheumatoid factor.
*Refers to the number of patients who had sera available for CCP assays.

2nd MBL Test ng/ml

4000

3000

2000

R2 = 0.81

1000

0
0

1000

2000

3000

4000

1st MBL Test ng/ml

FIGURE 1. Correlation between the 1st and 2nd mannose binding
lectin (MBL) test (n ¼ 331). R2 ¼ 0.81 (complete data set).
The dotted lines indicate the grouping (namely <56 ng/mL and
<1300 ng/mL) used in our study.

54 (minor allele B), and 57 (minor allele C) SNPs are all located
on exon 1. The major allele is named allele A (no SNP). The
presence of any minor allele (sometimes collectively named the O
allele) results in a signiﬁcant reduction of serum MBL concentrations, with homozygosity or a combination of minor alleles
resulting in very low or almost absent serum MBL concentrations. There are also additional SNPs in the promoter region of
the gene that can inﬂuence MBL concentration, resulting in
some individuals with AA or AO genotypes that also have

reduced concentrations.17 In the laboratory, 731 specimens were
screened for the presence of homozygous or heterozygous minor
allele while concurrently measuring serum MBL concentrations.
In this laboratory cohort 132 of 731 had an MBL concentration
of <56 ng/mL; 128 of 132 (97%) carried at least 1 minor allele;
mutations in minor allele B (codon 54) were the most common;
with the homozygous presence of minor allele B in 28 of 132
(21%) and the heterozygous presence of minor allele B in 58 of
132 (44%), 34 of these 58 had an additional variation in codon
52 or 57.

MBL genotyping
Genotyping was performed by PCR-restriction fragment
length polymorphism based on the method described by
Madsen et al.18
In the RA cohort, we performed MBL genotype testing in
19 of the 34 participants with MBL concentrations <56 ng/mL.
All 19 carried at least 1 minor allele (5 homozygous variation and
7 heterozygous variation at minor allele B; 1 homozygous
variation and 3 heterozygous variation at minor allele D; 2
with heterozygous variation at minor allele B and D; 1 with
heterozygous variation at minor allele C).
Thus, in these data sets, undetectable concentrations of serum
MBL of <56 ng/mL were highly indicative of the presence of
minor alleles and the allele determination in those with low
serum levels offered very little additional clinical information. On
the other hand, participants with very high concentrations of
MBL above 1300 ng/mL can still have heterozygous variation
within codons 52, 54, and 57, but in this concentration range,
no homozygosity for minor alleles was detected in this cohort.
This indicates that genotyping alone without performing serum
MBL concentrations may be misleading, unless variation in the
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promoter regions, which inﬂuence expression levels, is also being
considered.
Thirty-three participants in this study had undetectable MBL
(14.5%), which is higher than the background rate in comparable
Caucasian populations for whom such data have been reported
and also higher than in the RA cohort studied by Saevarsdottir
et al,13 who reported undetectable MBL in just under 10% of
330 healthy volunteers and blood donors and in just under 8% of
an early RA cohort in Iceland. In this study, 20 of the 33 patients
with undetectable MBL (61%) developed 1 or more SIs. Patients
with RA with undetectable MBL had an odds ratio (OR) for an
SI of 4.67. As can be seen in Figure 2, participants with undetectable MBL had signiﬁcantly higher rates of SIs in the whole
group and also in the sDMARD and the bDMARD subsets.
The incidence of SIs by MBL concentration and prednisolone
dose was examined (Figure 3). It can be seen that the SI rate was
a function of both MBL concentration and corticosteroid dosage.
Participants with an undetectable MBL who were taking prednisolone at a dose greater than 5 mg per day were found to have
the highest susceptibility to SIs with a rate of 68 per 100 patient
years (PYs) in comparison to 6 per 100 PYs for those taking less
than 5 mg per day of prednisolone in whom MBL was detectable
and 20 per 100 PYs in those taking greater than 5 mg per day of
prednisolone in whom MBL was detectable. The possibility of
synergy between undetectable MBL and higher dose prednisolone was considered. Tests for an interaction between MBL and
prednisolone did not support synergy (P ¼ .203). During the
almost 6-year period of observation, approximately 12 versus 9
SIs per 100 PYs were recorded for synthetic and biologic
DMARD recipients, respectively. Thus, no substantive difference in SI rates was observed.
The types and frequencies of SIs according to treatment
category are shown in Tables II and III. Amongst this cohort,
pneumonia and other respiratory tract infections were the most
common SI occurring in 39.2% of all participants with 1 or
more SIs and dominating in both the synthetic and biologic
treatment groups. A signiﬁcantly higher frequency of respiratory
tract infections was observed in recipients of sDMARDs
(P < .045). Skin infections of all types accounted for 19.6% of
SIs and trended toward a higher frequency in biologic recipients,
but the difference was not statistically signiﬁcant. Urological
infections occurred in 13.3% and joint, bone, and muscle infections combined occurred in 10.5%. There was no signiﬁcant
difference in the rate of septic arthritis between the 2 groups;
rates observed were 7.2% for the bDMARD group and 3.3% for
the sDMARD group (P ¼ .48). The type and frequency of SIs in
bDMARD recipients are set out in more detail in Table III.
Musculoskeletal infections were overrepresented in the etanercept recipients.
There were 22 deaths over the observation period: 11
(8.3%) in the biologic DMARD group (n ¼ 132) and 11
(11.4%) in the synthetic DMARD group (n ¼ 96). Of these
22 deaths, in 7 patients an SI was the primary cause of death
(6 respiratory tract infections of which 4 were in the biologic
DMARD group and 2 in the synthetic DMARD group; and 1
urinary tract infection with septicemia in the synthetic
DMARD group). Amongst these 7 infection-related deaths, 3
had undetectable MBL and 3 had MBL in the range 56 to
1300 ng/mL.
Age was another signiﬁcant predictor of SIs. For every 5-year
increase in age, there was a 19% increase in the risk of an SI
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(IRR ¼ 1.19, 95% CI 1.06-1.33) using negative binomial
regression. For every 10-year increase in age, there was a 41%
increase in the risk of an SI (IRR ¼ 1.41, 95% CI 1.12-1.77).
Gender, smoking, diabetes, chronic obstructive pulmonary disease (COPD), low neutrophil or lymphocyte counts, and low
immunoglobulin concentrations did not confer increased risk for
SIs in our cohort.
SIs occurred in 23 of the 30 participants who were receiving CS
(77%). The median dose of prednisolone in these 23 participants
was 7 mg per day (range 3-20 mg/day). IRRs for SIs according to
corticosteroid dosage were determined by a negative binomial
model. Compared with no CS, the IRR for an SI with a dose of
1 to 4.5 mg of prednisolone per day was 2.57, for 5 to 9.5 mg per
day it was 3.38, and for doses of 10 mg per day or more it was
4.70. Thus, severe MBL deﬁciency confers a risk for an SI similar
to that of regular use of prednisolone 10 mg per day.
Multiple SIs (2 or more) were observed in 30 patients with RA
(13.2%), 9 of whom had undetectable MBL concentrations
and 16 of whom had MBL concentrations 600 ng/mL
(OR ¼ 4.01, CI 1.40-11.45, P ¼ .009).
There have been reports indicating that MBL deﬁciency is
associated with chronic lung infections such as in cystic
ﬁbrosis.19 When we examined the relationship between MBL
deﬁciency and all nonpulmonary SIs in this cohort, a strong
association between undetectable MBL concentrations and SIs
was still observed for all of these infections taken together, but
most commonly for bone, joint, and muscle infections combined
(11 of the 15 participants with bone, joint, and muscle infection
had an undetectable MBL concentration).

DISCUSSION
Serious infections are a major cause of morbidity and
mortality in RA. This observational data audit shows that undetectable MBL (OR ¼ 4.67) and CS use (prednisolone dose of
10 mg per day or higher, OR ¼ 4.70) confer high risk for an SI.
Increasing age was also found to be another signiﬁcant, but lesser
predictor of an SI. MBL deﬁciency is a hitherto unrecognized
risk factor for an SI in RA.
Crowson et al in a series of studies addressing SIs in RA
identiﬁed several major risk factors, notably increased age and CS
use. They also showed that extra-articular manifestations of RA
and comorbidities such as chronic lung disease, coronary artery
disease, peripheral vascular disease, organic brain disease, diabetes
mellitus, chronic renal disease, and alcoholism were associated
with increased SI risk.1,2 Furthermore, a previous SI was shown
to predict subsequent SIs, a risk that we were unable to evaluate
in this cohort.
The ﬁndings reported here indicate that an undetectable MBL
concentration is an important risk factor for both single and
multiple or recurrent SIs in RA with IRRs comparable with those
of moderate dose maintenance CS therapy. Amongst those patients with RA with an undetectable MBL concentration, the rate
of SIs was 25 per 100 PYs (95% CI 18.1-31.9), which was
substantially higher than that for patients with RA with a
detectable MBL (8 per 100 PYs, P < .001). Furthermore, these
ﬁndings indicate that MBL deﬁciency confers a higher risk for an
SI than age, tobacco consumption, COPD, or type 1 diabetes
mellitus and type 2 diabetes mellitus. It is worth noting that no
patient aged less than 50 years with MBL concentrations greater
than 56 ng/mL and taking <5 mg of prednisolone per day
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FIGURE 2. Number of serious infections per hundred patient years according to MBL concentrations or prednisolone dose; participants
treated with biologic DMARDs (n ¼ 132) or synthetic DMARDs (n ¼ 96). “Pred” denotes prednisolone, “Biologics” denotes biologic
DMARDs, and “Non-Biologics” denotes synthetic DMARDs. DMARD, Disease-modifying antirheumatic drug; MBL, mannose binding
lectin; PY, patient year.

(n ¼ 16) developed an SI over the median 5.9 years of observation, whereas all 6 patients aged over 65 years with undetectable MBL concentrations and taking 5 mg of prednisolone
each day developed 1 or more SIs (6.5-fold increase in the risk of
an SI [IRR ¼ 6.49, 95% CI 4.07-9.97, P < .001]).
To date, there is limited published evidence addressing
changes in MBL concentration over time and in particular,
during the time of acute infection or disease ﬂares. Longitudinal
data by Auriti et al20 showed that neonates with nosocomial
sepsis had a signiﬁcantly higher median MBL concentration after
the onset of infection compared with the admission concentration. The MBL concentration decreased commonly after resolution of infection, although a large variation in pattern was seen
overall. Takahashi et al21 investigated changes in MBL concentration over time in a subset of 14 patients with newly diagnosed
systemic lupus erythematosus to assess the impact of treatment
on MBL. In this study, MBL concentrations rose in 6 of 14
patients and declined in 7 patients, whereas 1 patient showed no

change. There was no signiﬁcant association between an increase
or a decrease of serum MBL concentration, MBL genotype, or
clinical characteristics. We addressed the question of variability of
MBL concentrations over time, by analyzing retrospective data
from the local immunodiagnostic laboratory, in addition to
randomly performed repeat measurements of MBL in this RA
cohort. Both datasets showed that repeat measurements were
highly correlated, especially in persons with lower MBL
concentrations or undetectable MBL. Additionally, the genotypic analysis presented here indicated that undetectable MBL
was highly indicative of the presence of minor alleles. Allele
determination in those persons provided little additional
information.
On the basis of the limited evidence available so far, the
authors recommend that the concentration of MBL should be
determined when the patient is clinically well with no evidence
of an acute infection or disease ﬂare, for example, normal range
C-reactive protein, as occurred mostly in this study.
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FIGURE 3. The incidence of serious infections (SIs) by mannose binding lectin (MBL) concentration (undetectable or detectable) and dose
of prednisolone (0-5 mg and >5 mg). A much higher rate of SIs was observed in participants with undetectable MBL who were receiving a
prednisolone dose >5 mg (68 per 100 patient years of treatment or observation). Statistical tests for an interaction between MBL and
prednisolone did not support synergy (P ¼ .203).

TABLE III. Types of serious infections and biologic DMARDs

Abatacept
Adalimumab
Etanercept
Inﬂiximab
Rituximab
Tocilizumab
Total

Resp

Urological

Gastro

Skin

Sept

Joint

Bone

Other

5
14
1

7
4

2
2
3

4
16

5
2

11

6

1
2

1
1
13

7

1
21

1
8

11

6

3

3
23

Resp denotes respiratory; Gastro denotes gastrointestinal; Sept denotes septicemia.
DMARD, Disease-modifying antirheumatic drug.

Interestingly, musculoskeletal SIs amongst bDMARD users
were restricted to etanercept recipients. A similar observation was
made in the German Biologics Registry, referred to as RABBIT,
in which 5 of 512 etanercept-treated patients with RA developed
septic arthritis, whereas only 1 of 346 inﬂiximab recipients and
1 of 601 RA controls not taking tumor necrosis factor inhibitors
developed septic arthritis.22 In RABBIT, the difference was not
statistically signiﬁcant. Further studies are required to determine
whether etanercept confers increased and selective risk for
musculoskeletal sepsis.
It is well recognized that the use of CS is associated with an
increased risk for serious infection, both in RA and other diseases. Doses of prednisolone 10 mg or more were associated with
88 SIs per 100 PYs in this study, which is well above the rate of
7 per 100 PYs encountered amongst patients with RA taking
prednisolone at a dose of less than 5 mg per day (P ¼ .012).
One of the strengths of this observational data audit is the
longitudinal observation, which has allowed SIs to be captured
well beyond the usual time frame applicable to clinical trials
and in particular randomized controlled trials. Furthermore, the
ascertainment of SIs did not rely heavily on self-reporting, as is
the case for some registries or on physician reporting, where
compliance can be an issue, but rather is the product of regular
questioning by a physician, cross-referencing against hospital

discharge summaries and a comprehensive audit. Importantly,
no patient was excluded from cohort entry because of previous
SIs. Thus, a high degree of SI ascertainment, reﬂecting
real-world experience, is likely to have been achieved. Weaknesses include the absence of a large non-RA or untreated RA
control group and the heterogeneous nature of the RA study
population with a bias toward more severe biologic DMARDtreated RA. Many biologic agents are underrepresented
because of the data audit commencement date in 2007.
Furthermore, over time, changing from one agent to another
became increasingly common, thus complicating between biologic comparisons. Small numbers limited the assessment of
combinations of risk factors, such as the combination of undetectable MBL concentrations and prednisolone dose of 10
mg or more in the same participant (n ¼ 2). It is also noteworthy that the number of participants in special interest
subsets, such as Felty’s syndrome, RA with hypogammaglobulinemia, and RA with neutropenia, were too few to permit deep
analysis. Because of the predominant Caucasian ethnicity of the
participants, the ﬁndings may not be generalizable to other
racial groups.
The observation of a similar rate of SIs in recipients of synthetic
and biologic DMARDs was unexpected, but not entirely out of
keeping with the longer term observational nature of this study
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and the rigorous review of SIs that was undertaken by means of
hospital record audit. Large meta-analyses, such as that of Singh
et al,23 showed no statistically signiﬁcant increase in SIs for low
dose biological drugs with or without synthetic DMARD therapy,
but did note increases for standard dose, high dose, and especially
combination biological drugs. It should be noted, however, that
most of the studies on which they relied were short-term
controlled trials (less than 1 year) with a placebo comparator
and from which an indeterminate number of patients including
the elderly may have been excluded. A higher rate of SIs in biologic recipients in the ﬁrst year of therapy may contribute to the
differences between meta-analyses based mainly on controlled
trials and the ﬁndings in this longer term observational study.
Whether MBL replacement can protect against SIs or be
useful for the treatment of an established SI in a critically ill
patient remains unknown, but warrants further consideration in
the light of these ﬁndings and the studies already underway to
ascertain whether MBL replacement may improve outcomes in
MBL-deﬁcient neonates with septicemia.19,24
In the meantime, because serious infections in RA are
common and potentially life threatening, clinicians should
carefully consider SI risk factors before making therapeutic
decisions in patients about to begin or change synthetic or
biologic DMARDs. Throughout therapy, a high level of
vigilance is required for both synthetic and biologic DMARD
recipients, but especially in those who are elderly, receiving
corticosteroids and now also we suggest, those with undetectable MBL concentrations.
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